New research from Roswell Park Comprehensive Cancer Center and MimiVax LLC, published in Clinical Cancer Research, shows that survivin — one of the most commonly occurring molecules in cancer cells — may be an attractive target for a broad range of immunotherapy approaches, including CAR T.